Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Many patients with tingling or numbness begin to notice a reduction over months two and three, with further recovery beyond six months
The path forward For 5-amino-1mq to move from research compound to established therapy, human clinical trials are needed
AOD-9604 adds a lipolytic component without further IGF-1 increase , useful in research contexts where you want lipolysis but not systemic anabolism
Pairing with Vitamin C may accelerate results
The mechanism of AOD 9604 in subcutaneous adipose tissue Activation of fat breakdown (lipolysis) AOD 9604 promotes fat breakdown through the following pathways: Activation of the 3-AR signaling pathway: AOD 9604 binds to 3-AR on the adipocyte membrane, activates adenylic acid cyclase (AC), increases the intracellular cyclic adenosine monophosphate (cAMP) level, and thereby activates protein kinase A (PKA)
Due to the limited data, it should be avoided by anyone who is pregnant, breastfeeding, or undergoing active cancer treatment
